Considering the multifaceted effects of mTOR inhibitors on different immune cells populations, a safe use of these drugs in combination with currently available immunotherapies for melanoma (ICI) will likely require extensive validation and schedule optimization in both preclinical and clinical settings, and needs also to take into account individual differences in the cellular composition of the immune cell tumor infiltrate. The gene discussed is MTOR; the disease is melanoma.